CN103517738A - 含有防晒剂的成膜组合物及其对疤痕进行处理的用途 - Google Patents
含有防晒剂的成膜组合物及其对疤痕进行处理的用途 Download PDFInfo
- Publication number
- CN103517738A CN103517738A CN201280021506.XA CN201280021506A CN103517738A CN 103517738 A CN103517738 A CN 103517738A CN 201280021506 A CN201280021506 A CN 201280021506A CN 103517738 A CN103517738 A CN 103517738A
- Authority
- CN
- China
- Prior art keywords
- compositions
- sunscreen
- mixture
- composition
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 115
- 231100000241 scar Toxicity 0.000 title abstract description 3
- 208000032544 Cicatrix Diseases 0.000 title abstract 2
- 230000037387 scars Effects 0.000 title abstract 2
- 239000002904 solvent Substances 0.000 claims abstract description 25
- 229920000642 polymer Polymers 0.000 claims abstract description 22
- 239000004014 plasticizer Substances 0.000 claims abstract description 11
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000012530 fluid Substances 0.000 claims abstract description 4
- 230000000475 sunscreen effect Effects 0.000 claims description 51
- 239000000516 sunscreening agent Substances 0.000 claims description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000000020 Nitrocellulose Substances 0.000 claims description 16
- -1 antifungal Substances 0.000 claims description 16
- 229920001220 nitrocellulos Polymers 0.000 claims description 16
- 241001597008 Nomeidae Species 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 13
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- 210000000589 cicatrix Anatomy 0.000 claims description 9
- 229960001679 octinoxate Drugs 0.000 claims description 8
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 claims description 3
- 229960005193 avobenzone Drugs 0.000 claims description 3
- 239000007854 depigmenting agent Substances 0.000 claims description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
- 239000003410 keratolytic agent Substances 0.000 claims description 3
- 229960002622 triacetin Drugs 0.000 claims description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical class [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 abstract description 4
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- 238000003756 stirring Methods 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000005855 radiation Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 229940114081 cinnamate Drugs 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 3
- 229960000601 octocrylene Drugs 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 2
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 2
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 2
- CNXZMGRWEYQCOQ-UHFFFAOYSA-N 2-methoxy-3-phenylprop-2-enoic acid Chemical compound COC(C(O)=O)=CC1=CC=CC=C1 CNXZMGRWEYQCOQ-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- XMEDXTRRSJHOLZ-KRWDZBQOSA-N [(6as)-9-acetyloxy-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-2-yl] acetate Chemical compound CN1CCC2=CC(OC(C)=O)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC(C)=O)=C1 XMEDXTRRSJHOLZ-KRWDZBQOSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000010478 argan oil Substances 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- SODJJEXAWOSSON-UHFFFAOYSA-N bis(2-hydroxy-4-methoxyphenyl)methanone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=C(OC)C=C1O SODJJEXAWOSSON-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 2
- OUDSFQBUEBFSPS-UHFFFAOYSA-N ethylenediaminetriacetic acid Chemical compound OC(=O)CNCCN(CC(O)=O)CC(O)=O OUDSFQBUEBFSPS-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 239000010460 hemp oil Substances 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- HJOVHMDZYOCNQW-UHFFFAOYSA-N isophorone Chemical compound CC1=CC(=O)CC(C)(C)C1 HJOVHMDZYOCNQW-UHFFFAOYSA-N 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004611 light stabiliser Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- OIQXFRANQVWXJF-LIQNAMIISA-N (1s,2z,4r)-2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound O=C([C@]1(C)CC[C@H]2C1(C)C)\C2=C/C1=CC=CC=C1 OIQXFRANQVWXJF-LIQNAMIISA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- URJOWNUVTORLNY-UHFFFAOYSA-N (5-hexadecanoyloxy-4-oxopyran-2-yl) hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC1=CC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=CO1 URJOWNUVTORLNY-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QTKIQLNGOKOPOE-UHFFFAOYSA-N 1,1'-biphenyl;propane Chemical group CCC.C1=CC=CC=C1C1=CC=CC=C1 QTKIQLNGOKOPOE-UHFFFAOYSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
- PKJBRKTYYNRVSN-UHFFFAOYSA-N 10-(aminomethyl)-9,10-dihydroanthracene-1,2-diol Chemical compound OC1=CC=C2C(CN)C3=CC=CC=C3CC2=C1O PKJBRKTYYNRVSN-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GJUXFTUISAQMQE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-ethylhexanoate;2,3-dimethoxy-3-phenylprop-2-enoic acid Chemical compound CCCCC(CC)C(=O)OCC(O)CO.COC(C(O)=O)=C(OC)C1=CC=CC=C1 GJUXFTUISAQMQE-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- LSHGMOIQPURPAK-UHFFFAOYSA-N 2-benzylidene-1,4,7,7-tetramethylbicyclo[2.2.1]heptan-3-one Chemical compound CC1(C)C(C2=O)(C)CCC1(C)C2=CC1=CC=CC=C1 LSHGMOIQPURPAK-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- NCIAZCLIFWUDPR-UHFFFAOYSA-N 2-butyl-3,4,5,6-tetramethylphenol Chemical compound CCCCC1=C(C)C(C)=C(C)C(C)=C1O NCIAZCLIFWUDPR-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 description 1
- PSZAEHPBBUYICS-UHFFFAOYSA-N 2-methylidenepropanedioic acid Chemical compound OC(=O)C(=C)C(O)=O PSZAEHPBBUYICS-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- ISDGWTZFJKFKMO-UHFFFAOYSA-N 2-phenyl-1,3-dioxane-4,6-dione Chemical group O1C(=O)CC(=O)OC1C1=CC=CC=C1 ISDGWTZFJKFKMO-UHFFFAOYSA-N 0.000 description 1
- CYSSSYKSBHKJQE-UHFFFAOYSA-N 2-undecylpentadecan-1-ol Chemical compound CCCCCCCCCCCCCC(CO)CCCCCCCCCCC CYSSSYKSBHKJQE-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000002629 Acer saccharinum Nutrition 0.000 description 1
- 244000046139 Acer saccharum Species 0.000 description 1
- 235000004421 Acer saccharum Nutrition 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 244000189799 Asimina triloba Species 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- ZNSMNVMLTJELDZ-UHFFFAOYSA-N Bis(2-chloroethyl)ether Chemical compound ClCCOCCCl ZNSMNVMLTJELDZ-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- LHJLRNTWTYWKAG-UHFFFAOYSA-N C(CCC)C(C(=O)O)(CCCCCCCC(=O)O)CCCC.C(CCCCCCCCC(=O)O)(=O)O Chemical compound C(CCC)C(C(=O)O)(CCCCCCCC(=O)O)CCCC.C(CCCCCCCCC(=O)O)(=O)O LHJLRNTWTYWKAG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 108010020326 Caspofungin Proteins 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 108010064699 MSH Release-Inhibiting Hormone Proteins 0.000 description 1
- 240000007794 Melaleuca viridiflora Species 0.000 description 1
- 235000017710 Melaleuca viridiflora Nutrition 0.000 description 1
- NOOJLZTTWSNHOX-UWVGGRQHSA-N Melanostatin Chemical compound NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 NOOJLZTTWSNHOX-UWVGGRQHSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- HFEQJOALZMHGHG-UHFFFAOYSA-N N1=NNC(C=C1)=O.C(CCC)(=O)NC(CCCCC)(CC)CC Chemical compound N1=NNC(C=C1)=O.C(CCC)(=O)NC(CCCCC)(CC)CC HFEQJOALZMHGHG-UHFFFAOYSA-N 0.000 description 1
- JOFHMNOLOPRHQV-INZIHYEWSA-N N1[C@@H](CCC1)C(=O)O.C(CCCCCCCCCCCCCCC)[Na] Chemical compound N1[C@@H](CCC1)C(=O)O.C(CCCCCCCCCCCCCCC)[Na] JOFHMNOLOPRHQV-INZIHYEWSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- 241000209490 Nymphaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 235000019497 Pistachio oil Nutrition 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 229920002396 Polyurea Polymers 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- SYCBXBCPLUFJID-UHFFFAOYSA-N Pramoxine hydrochloride Chemical compound Cl.C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 SYCBXBCPLUFJID-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000005805 Prunus cerasus Nutrition 0.000 description 1
- 240000002878 Prunus cerasus Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241001050807 Rumex occidentalis Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- SZAMSYKZCSDVBH-CLFAGFIQSA-N [(z)-octadec-9-enyl] (z)-docos-13-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OCCCCCCCC\C=C/CCCCCCCC SZAMSYKZCSDVBH-CLFAGFIQSA-N 0.000 description 1
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 1
- JKNZUZCGFROMAZ-UHFFFAOYSA-L [Ag+2].[O-]S([O-])(=O)=O Chemical compound [Ag+2].[O-]S([O-])(=O)=O JKNZUZCGFROMAZ-UHFFFAOYSA-L 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- BJRNKVDFDLYUGJ-ZIQFBCGOSA-N alpha-Arbutin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-ZIQFBCGOSA-N 0.000 description 1
- XNCRUNXWPDJHGV-UHFFFAOYSA-N alpha-Methyl-cinnamic acid Chemical compound OC(=O)C(C)=CC1=CC=CC=C1 XNCRUNXWPDJHGV-UHFFFAOYSA-N 0.000 description 1
- XYLMUPLGERFSHI-UHFFFAOYSA-N alpha-Methylstyrene Chemical compound CC(=C)C1=CC=CC=C1 XYLMUPLGERFSHI-UHFFFAOYSA-N 0.000 description 1
- 229940033280 alpha-arbutin Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960003204 amorolfine Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- WXNRYSGJLQFHBR-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O WXNRYSGJLQFHBR-UHFFFAOYSA-N 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 1
- 229960003034 caspofungin Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- CMDKPGRTAQVGFQ-RMKNXTFCSA-N cinoxate Chemical compound CCOCCOC(=O)\C=C\C1=CC=C(OC)C=C1 CMDKPGRTAQVGFQ-RMKNXTFCSA-N 0.000 description 1
- 229960001063 cinoxate Drugs 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical group O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 229940090959 diacetyl boldine Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- TVFJAZCVMOXQRK-UHFFFAOYSA-N ethenyl 7,7-dimethyloctanoate Chemical compound CC(C)(C)CCCCCC(=O)OC=C TVFJAZCVMOXQRK-UHFFFAOYSA-N 0.000 description 1
- MFGZXPGKKJMZIY-UHFFFAOYSA-N ethyl 5-amino-1-(4-sulfamoylphenyl)pyrazole-4-carboxylate Chemical compound NC1=C(C(=O)OCC)C=NN1C1=CC=C(S(N)(=O)=O)C=C1 MFGZXPGKKJMZIY-UHFFFAOYSA-N 0.000 description 1
- TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002782 merbromin Drugs 0.000 description 1
- SQFDQLBYJKFDDO-UHFFFAOYSA-K merbromin Chemical compound [Na+].[Na+].C=12C=C(Br)C(=O)C=C2OC=2C([Hg]O)=C([O-])C(Br)=CC=2C=1C1=CC=CC=C1C([O-])=O SQFDQLBYJKFDDO-UHFFFAOYSA-K 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- AKFJWRDCWYYTIG-ZDUSSCGKSA-N naproxcinod Chemical compound C1=C([C@H](C)C(=O)OCCCCO[N+]([O-])=O)C=CC2=CC(OC)=CC=C21 AKFJWRDCWYYTIG-ZDUSSCGKSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- CCCMONHAUSKTEQ-UHFFFAOYSA-N octadecene Natural products CCCCCCCCCCCCCCCCC=C CCCMONHAUSKTEQ-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940120511 oleyl erucate Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- FZUGPQWGEGAKET-UHFFFAOYSA-N parbenate Chemical compound CCOC(=O)C1=CC=C(N(C)C)C=C1 FZUGPQWGEGAKET-UHFFFAOYSA-N 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 1
- 229960000247 phenylmercuric borate Drugs 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000010471 pistachio oil Substances 0.000 description 1
- 229940082415 pistachio oil Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- DENZXURVSCIFJK-UHFFFAOYSA-N propylbenzene sulfamide Chemical compound S(=O)(=O)(N)N.C(CC)C1=CC=CC=C1 DENZXURVSCIFJK-UHFFFAOYSA-N 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 description 1
- 229950004154 ravuconazole Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229940062013 tamarind extract Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- LYDRKKWPKKEMNZ-UHFFFAOYSA-N tert-butyl benzoate Chemical group CC(C)(C)OC(=O)C1=CC=CC=C1 LYDRKKWPKKEMNZ-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- KOZCZZVUFDCZGG-UHFFFAOYSA-N vinyl benzoate Chemical compound C=COC(=O)C1=CC=CC=C1 KOZCZZVUFDCZGG-UHFFFAOYSA-N 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/95—Involves in-situ formation or cross-linking of polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
本发明涉及至少含有聚合物、增塑剂、挥发性溶剂和极少量有机防晒剂的流体组合物，相对于该组合物的总重量，所述防晒剂约为0.5wt%-2.2wt%。这一旨在施用至皮肤的组合物可用于对疤痕进行处理。此外，所述组合物优选含有二苯甲酰基甲烷衍生物和肉桂酸酯衍生物。
Description
技术领域
本发明涉及至少含有聚合物、增塑剂、挥发性溶剂以及极少量有机防晒剂（sun filter）的液态敷料。这一组合物旨在施用至皮肤上以用防水膜覆盖皮肤，可有利地将所述组合物用于对疤痕进行处理。
背景技术
疤痕特别脆弱，不仅对外部病原体敏感，而且对来自太阳的紫外（UV）线也敏感。
已经在商业上推出了多种用于保护疤痕、尤其是针对UV辐射的产品。其中的部分产品处于乳液面霜（emulsion cream）的形式，并含有大量的水。这些水基产品包含非常高含量的防晒剂（约为10wt%-35wt%）以确保抗紫外辐射的适宜效果。
文献US 7241451中描述了含有2wt%-7.5wt%奥西诺酯（octinoxate）和0.5wt%-7.5wt%氧化锌的疤痕消除面霜。然而，这一面霜具有防水性差的缺点，一旦皮肤与水接触，对疤痕的日光保护作用便消失。此外，这一类型的面霜具有不耐揉擦的缺点。
此外，这些制剂中所含的防晒剂倾向于以一定的比例渗入皮肤中，因此，为确保有效地保护皮肤抵抗UV辐射，该组合物必须含有高比例的有机防晒剂。
在挥发性溶剂中配制的液态敷料通常处于流体形式，使用合适的涂敷器（例如喷雾器、刷子或抹刀等）将该液态辅料施用于皮肤上。挥发性溶剂在与皮肤接触时蒸发，从而留下保护皮肤的固态膜。
由于所形成的膜为固态并保留在表面，在皮肤上成膜的液态敷料提供了限制成分向皮肤中渗入的优点。此外，由于这些膜防水且耐揉擦，因此在施用后，这些膜可维持数天。
文献FR 2929522中给出了含有大量有机防晒剂和无机防晒剂的、处于溶剂相中的液态敷料。然而，本申请人证实了无机防晒剂会随时间而沉降，从而使组合物在储存中不稳定。
此外，与这一文献的教导相反的是，本申请人已经证明，为获得有效的UV保护作用，无需加入无机防晒剂。因此，对于将被加入到处于溶剂相的液态敷料中的防晒剂，本申请人对上述防晒剂的性质和量进行了优化。
再者，本申请人出乎意料地发现，在这一类型的制剂中，即使在照射后，有机防晒剂丁基甲氧基二苯甲酰基甲烷（阿伏苯宗）仍然具有高的日光保护能力，因而无需向该制剂中加入通常与该有机防晒剂结合使用的光稳定剂、例如氰双苯丙烯酸辛酯（octocrylene）。
因此，本发明提供了具有令人满意的UV吸收作用的液态敷料，所述液态敷料使用有限量的防晒剂、优选有机防晒剂。
发明内容
因此，本发明涉及旨在施用于皮肤上的流体组合物，所述组合物含有聚合物、增塑剂、除水以外的所述聚合物的挥发性溶剂、以及至少一种有机防晒剂；其特征在于，相对于该组合物的总重量，防晒剂的总含量为0.5wt%-2.2wt%，挥发性溶剂占该组合物总重量的60wt%-90wt%，所述聚合物以干重计占该组合物总重量的5wt%-20wt%。
在施用本发明的组合物后，所述聚合物优选能在皮肤上形成连续的膜。所述聚合物优选为水不溶性，并且一旦组合物中的挥发性溶剂蒸发即形成水不溶性膜。例如，羟丙基纤维素和羟乙基纤维素不会形成干燥的水不溶性膜。所述聚合物优选可溶于挥发性溶剂而非水中。
聚合物可选自：天然来源的聚合物；瓜尔胶；阿拉伯树胶；海藻酸盐/酯；黄原胶；明胶；壳聚糖；硅酸盐/酯；水合氧化硅；聚氨基甲酸酯；聚酯；聚酯酰胺；聚酰胺；聚脲；乙烯基聚合物；丙烯酸聚合物；聚乙烯醇缩丁醛；醇酸树脂；来自醛缩合产物的树脂，如芳基磺酰胺甲醛树脂、芳基磺酰胺环氧树脂、乙基甲苯磺酰胺树脂、苯乙酮/甲醛树脂；以及上述物质的混合物。
乙烯基聚合物可由单体均聚或共聚得到，所述单体选自：乙烯基酯，如乙酸乙烯酯、新癸酸乙烯酯、新戊酸乙烯酯、苯甲酸乙烯酯和苯甲酸叔丁基乙烯酯；以及苯乙烯单体，如苯乙烯和α-甲基苯乙烯。
丙烯酸聚合物可为丙烯酸的均聚物、丙烯酸的共聚物、甲基丙烯酸的均聚物或甲基丙烯酸的共聚物。
根据一个实施方式，聚合物选自纤维素聚合物，尤其是羟丙基甲基纤维素、纤维素醚、纤维素酯、硝化纤维素、水不溶性纤维素衍生物、以及上述物质的混合物。
根据一个实施方式，聚合物为硝化纤维素，优选选自高粘度硝化纤维素。尤其是可使用具有美国标准RS 1/2″至RS 20″级（相当于欧洲标准8E-21E级）的硝化纤维素。例如，优选10E或11E级（相当于美国标准RS 15″级）的硝化纤维素。
尤其是，硝化纤维素选自：HERCULES公司销售的RS 5″和RS 15″硝化纤维素；Nobel公司销售的
120/170、
25/45或
40/70产品；Wolff Cellulosics生产的E
和E
硝化纤维素；以及SNPE-Bergerac以
和名称销售的产品。可提供干燥形式或处于溶剂（如异丙醇或乙醇）中的溶液形式的硝化纤维素。
相对于组合物的总重量，聚合物优选以干重计5wt%-20wt%、例如6wt%-15wt%、或甚至6wt%-9wt%的含量存在。
增塑剂可使膜更加柔韧。增塑剂优选选自植物来源的油及其乙氧基化衍生物。所述植物油可为：
优选选自于下述物质的植物油：芝麻油、蓖麻油、杏仁油、芥花油（canola oil）、榛子油、开心果油（pistachio oil）、亚麻籽油、琉璃苣油、大麻籽油（hemp oil）、霍霍巴油（jojoba oil）、葵花油、小麦胚芽油、玉米油和/或玉米胚芽油、花生油、鳄梨油、红花油、菜籽油、橄榄油、摩洛哥坚果油（argan oil）、葵花油、葡萄籽油、大豆油、核桃油、南瓜籽油、棕榈油、椰子仁油（copra oil）及上述物质的混合物。
该油还可为上述植物油之一的衍生物。该油可为氢化油或非氢化油、过氧化油或非过氧化油。
增塑剂还可选自：
-一元羧酸酯，如异壬酸异壬酯、芥酸油酯或新戊酸辛基-2-十二烷基酯；
-脂肪醇，如辛基十二烷醇、2-丁基辛醇、2-己基癸醇、2-十一烷基十五烷醇和油醇；
-脂肪酸，如油酸、亚油酸和亚麻酸；
-二醇及其衍生物，如二乙二醇乙基醚、二乙二醇甲基醚、聚乙二醇和聚丙二醇；
-二羧酸酯，如柠檬酸酯（柠檬酸乙酰三丁酯）、邻苯二甲酸酯（邻苯二甲酸二丁酯）、己二酸酯、癸二酸酯（癸二酸二丁酯）；
-甘油三乙酸酯（triacetin）或三乙酸甘油酯（glyceryl triacetate）；
-甘油；
-上述物质的混合物。
增塑剂优选可溶于聚合物的溶剂中。
有利的是，增塑剂和聚合物以0.5-1.5、优选0.7-1.2、更尤其是接近1的重量比存在于本发明所述组合物中。
在本发明的上下文中，有机防晒剂是指吸收波长通常为280-400nm的紫外辐射的任何有机化合物。本发明所使用的有机防晒剂可为过滤波长为320-400nm的UV-A辐射的化合物、过滤波长为280-320nm的UV-B辐射的化合物、过滤UV-A和UV-B辐射的化合物、或上述化合物的混合物。
相对于组合物的总重量，该组合物优选包含低于0.5wt%、更优选低于0.2wt%的无机防晒剂。
本发明的组合物优选不含无机防晒剂。
组合物中的防晒剂的总量低，相对于组合物的总重量，优选为0.5wt%-2.2wt%、更优选1.2wt%-1.8wt%、优选约1.5wt%。
有机防晒剂可选自：在UV-A方面有效的有机防晒剂、在UV-B方面有效的有机防晒剂、在UV-A和UV-B方面有效的有机防晒剂及上述物质的混合物。
在UV-A方面有效的有机防晒剂优选选自：
-二苯甲酰基甲烷衍生物，例如尤其是以商品名
1789销售的丁基甲氧基二苯甲酰基甲烷（INIC名称）或阿伏苯宗（USAN名称），或者异丙基二苯甲酰基甲烷；
-尤其是SYMRISE以NEO
MA名称销售的邻氨基苯甲酸甲酯；
-上述物质的混合物。
本发明的组合物优选在未混有光稳定剂（如氰双苯丙烯酸辛酯）的情况下，包含二苯甲酰基甲烷衍生物。根据一个实施方式，向二苯甲酰基甲烷衍生物中加入吸收UV-B的脂溶性有机防晒剂。
相对于组合物的总重量，在UV-A方面有效的有机防晒剂、特别是二苯甲酰基甲烷衍生物的含量低于1wt%、例如为0.2wt%-0.8wt%、优选0.3wt%-0.7wt%、更优选约0.5wt%。
组合物可含有在UV-B方面有效、优选脂溶性的防晒剂，所述防晒剂可选自：仅吸收波长位于UV-B的防晒剂、同时吸收UV-A和UV-B的防晒剂及其混合物。
仅在UV-B方面有效的防晒剂选自：
-水杨酸衍生物：尤其是以NEO
HMS名称销售的水杨酸三甲环己酯（homosalate）、尤其是SYMRISE以NEO
OS名称销售的水杨酸乙基己酯、尤其是以NEOtype05名称销售的水杨酸辛酯；
-肉桂酸酯：尤其是DSM Nutritional Products公司以商品名
MCX销售的甲氧基肉桂酸乙基己酯；甲氧基肉桂酸异丙酯；尤其是SYMRISE以商品名NEOE1000销售的甲氧基肉桂酸异戊酯；甲基肉桂酸二异丙酯；西诺沙酯（cinnoxate）；乙基己酸-二甲氧基肉桂酸甘油酯（glyceryl ethylhexanoate-dimethoxycinnamate）；
-亚苄基樟脑衍生物：CHIMEX以
SD名称制造的3-亚苄基樟脑；尤其以NEOMBC名称销售的甲基亚苄基樟脑；
-三嗪衍生物：尤其是BASF以商品名
T150销售的乙基己基三嗪酮；以商品名
HEB销售的二乙基己基丁酰胺三嗪酮；双-乙基己氧基酚甲氧基苯基三嗪；
-对氨基苯甲酸酯，如PABA乙酯、二羟基丙基PABA乙酯和二甲基PABA乙基己酯（来自ISP的507）；
-咪唑啉衍生物：二甲氧基亚苄基二氧代咪唑啉丙酸乙基己酯（ethylhexyldimethoxybenzylidene dioxoimidazoline propionate）；
-苯亚甲基丙二酸盐/酯衍生物：具有苯亚甲基丙二酸根官能团的聚有机硅氧烷，例如尤其是DSM Nutritional Products公司以商品名
SLX销售的聚硅酮-15；4′-甲氧基苯亚甲基丙二酸二新戊酯；
-以及上述物质的混合物。
同时在UV-A和UV-B方面有效的防晒剂可选自：
-二苯甲酮衍生物：以商品名
400销售的二苯甲酮-1、以商品名UVINUL D50销售的二苯甲酮-2、以商品名
M40销售的二苯甲酮-3或氧苯酮、以商品名
MS40销售的二苯甲酮-4、以商品名HELISORB 11销售的二苯甲酮-6、以商品名
UV-24销售的二苯甲酮-8；
-苯基苯并三唑衍生物：尤其是RHODIA CHIMIE以
名称销售的甲酚曲唑三硅氧烷、尤其是FAIRMOUNT CHEMICAL以商品名
BB/100以固态形式销售的亚甲基双苯并三唑基四甲基丁基酚；
-双-间苯二酚基三嗪衍生物：尤其是CIBA GEIGY以商品名
销售的双-乙基己氧基酚甲氧基苯基三嗪；
-苯并噁唑衍生物：尤其是Sigma3V以K2A名称销售的2,4-双-[5-1(二甲基丙基)苯并噁唑-2-基-(4-苯基)-亚氨基]-6-(2-乙基己基)-亚氨基-1,3,5-三嗪；
-以及上述物质的混合物。
根据本发明的一个实施方式，有机防晒剂为吸收UV-A的防晒剂和过滤UV-B的防晒剂的混合物。
例如，可向在UV-A方面有效的有机防晒剂中加入选自肉桂酸酯的脂溶性UV-B防晒剂、尤其是以商品名
MCX销售的甲氧基肉桂酸乙基己酯（INCI名称）或奥西诺酯（USAN名称）。
有机防晒剂可为丁基甲氧基二苯甲酰基甲烷（USAN名称为阿伏苯宗）和甲氧基肉桂酸乙基己酯（USAN名称为奥西诺酯）的混合物。
相对于组合物的重量，本发明组合物中的脂溶性有机UV-B防晒剂、尤其是甲氧基肉桂酸乙基己酯的含量优选低于1.2wt%、例如0.5wt%-1.2wt%、优选0.8wt%-1.2wt%、更优选约1wt%。
根据一个实施方式，二苯甲酰基甲烷衍生物和肉桂酸酯衍生物的重量比为0.3-0.7、优选约0.5。
相对于组合物的总重量，包含二苯甲酰基甲烷衍生物和肉桂酸酯衍生物的有机防晒剂以0.5wt%-2.2wt%、优选1.2wt%-1.8wt%、更优选约1.5wt%的量存在。
本发明的组合物还含有挥发性溶剂，所述挥发性溶剂优选溶解聚合物和增塑剂。这使得能够对成分进行溶解和均化，并且其挥发特性有助于施用后在皮肤上形成连续的固态膜。
在本发明的上下文中，挥发性溶剂是指与皮肤接触时能够快速蒸发的溶剂。该定义中不包括水。挥发性溶剂或挥发性溶剂的混合物优选沸点高于50℃（在大气压下）。
作为可使用的溶剂，可提及：
-酮，如甲基乙基酮、甲基异丁基酮、二异丁基酮、异佛尔酮、环己酮和丙酮；
-醇，如乙醇、异丙醇、正丙醇、正丁醇、二丙酮醇、2-丁氧基乙醇和环己醇；
-二醇，如乙二醇、丙二醇、戊二醇和丙三醇；
-丙二醇醚，如丙二醇单甲基醚、丙二醇单甲基醚乙酸酯和二丙二醇单正丁基醚；
-酯，如乙酸乙酯、乙酸甲酯、乙酸丙酯、乙酸正丁酯和乙酸异戊酯；
-甲缩醛；
-醚，如二乙醚、二甲醚或二氯二乙基醚；
-硅酮溶剂，尤其是六甲基硅氧烷和聚二甲基硅氧烷；
-上述物质的混合物。
挥发性溶剂优选选自乙醇、乙酸乙酯及它们的混合物。特别是，选择处于1/1至3/1、优选2/1比例的乙酸乙酯和乙醇的混合物。相对于组合物的总重量，挥发性溶剂的量优选为60wt%-90wt%、优选70wt%-90wt%。
组合物基本上不含水，优选组合物中含有低于2wt%的水。
本发明的组合物还可含有敷料制备中常用的添加剂，如芳香剂、防腐剂（preservatives）、脱色剂、抗细菌剂、抗真菌剂、愈合剂、止痛剂、消炎剂、保湿剂（hydrating agents）、角质层分离剂、维生素、甘油和柠檬酸。
通常，活性剂选自：
-抗细菌剂，如多粘菌素B、青霉素（阿莫西林）、克拉维酸、四环素、米诺环素、金霉素、氨基糖苷类、阿米卡星、庆大霉素、新霉素、银及其盐（磺胺嘧啶银）、益生菌；
-抗腐剂（antiseptics），如硫柳汞、伊红、氯己定、硼酸苯汞、过氧化氢、Dakin溶液、三氯生、双胍、己氧苯脒、百里酚、Lugol、聚维酮碘（iodinated povidone）、汞溴红、苯扎氯铵和苄索氯铵、乙醇、异丙醇；
-抗病毒剂，如阿昔洛韦、泛昔洛韦和利托那韦；
-抗真菌剂，如多烯、制霉菌素、两性霉素B、游霉素、咪唑类（咪康唑、酮康唑、克霉唑、益康唑、联苯苄唑、布康唑、芬替康唑、异康唑、奥昔康唑、舍他康唑、硫康唑、噻苯咪唑、噻康唑）、三唑类（氟康唑、伊曲康唑、雷夫康唑、泊沙康唑、伏立康唑）、烯丙胺、特比萘芬、阿莫罗芬、萘替芬、布替萘芬；
-氟胞嘧啶（抗代谢剂）、灰黄霉素、卡泊芬净、米卡芬净；
-止痛剂，如对乙酰氨基酚、可待因、右旋丙氧吩、曲马多、吗啡及其衍生物、肾上腺皮质激素和衍生物；
-消炎剂，如糖皮质激素、非甾体消炎剂、阿司匹林、布洛芬、酮洛芬、氟比洛芬、双氯芬酸、醋氯芬酸、酮咯酸、美洛昔康、吡罗昔康、替诺昔康、萘普生、吲哚美辛、萘普西诺、尼美舒利、塞来昔布、依托昔布、帕瑞昔布、罗非昔布、伐地昔布、保泰松、尼氟灭酸、甲芬那酸；
-促进愈合的活性剂，如视黄醇、维生素A、维生素E、N-乙酰基羟脯氨酸、积雪草（Centella Asiatica）提取物、木瓜蛋白酶、硅酮、百里香精油、绿花白千层精油、迷迭香精油和鼠尾草精油、透明质酸、具有1-4个单糖单元的合成多硫酸化寡糖（如蔗糖八硫酸钾盐、蔗糖八硫酸银盐或硫糖铝）、尿囊素；
-脱色剂，如曲酸（Kojic Acid
-Quimasso（Sino Lion））、熊果苷（
-Quimasso（Sino Lion））、棕榈酰脯氨酸钠和白色睡莲（
-Seppic）提取物的混合物、十一碳烯酰基苯丙氨酸（
-Seppic）、乙氧基乙二醇和曲霉发酵获得的甘草提取物（Gatuline 
-Gattefossé）、十八碳烯二酸（ODA
-Sederma）、α-熊果苷（
SACI-CFPA（Pentapharm））、熊果（Arctophylos Uva Ursi）叶水提物（
-SACI-CFPA（Pentapharm））、复合植物混合物Gigawhite
（SACI-CFPA（Alpaflor））、二乙酰基波尔定碱（Lumiskin
-Sederma）、日本蜜橘提取物（Melaslow
-Sederma）、富含柠檬酸的柠檬提取物和黄瓜提取物的混合物（
U-34-Unipex）、西酸模（Rumex occidentalis）提取物和维生素C的混合物（
11-Unipex）、寡肽（Melanostatin-Unipex）、曲酸二棕榈酸酯（KAD-
-Quimasso（Sino Lion））、来自LCW的天然来源复合物
小麦胚芽提取物（
II-Silab）、乙二胺三乙酸（EDTA）；
-角质层分离剂，如水杨酸、水杨酸锌、抗坏血酸、α-羟基酸（乙醇酸、乳酸、苹果酸、柠檬酸和酒石酸）、银槭提取物、摩利洛黑樱桃（morellocherry）树提取物、罗望子提取物、尿素、外用维甲酸
（Sederma公司）、枯草芽孢杆菌（Bacillus subtilis）发酵获得的蛋白酶、
产品（SACI-CFPA）、木瓜蛋白酶（来自木瓜果实的蛋白水解酶）；
-重组（restructuring）活性剂（例如用于附属物重组的活性剂），如氧化硅衍生物、维生素E、甘菊、钙、木贼提取物、Lipester de Soie；
-麻醉剂，如苯佐卡因、利多卡因、狄布卡因、盐酸普莫卡因、布比卡因、甲哌卡因、丙胺卡因、依替卡因。
如上所述，本发明的组合物处于旨在利用合适装置施用的流动液态形式。优选对所述组合物进行配制，以使其能够以多种可能的形式（尤其是以具有合适涂敷器（例如刷子或抹刀）的瓶、滚抹物的形式或以喷雾、唇膏或摩丝的形式）加以使用。
本发明进一步涉及上述组合物在保护疤痕中的用途。
根据一个实施方式，本发明所述的组合物旨在施用于与事故、疾病或随后的手术相关或无关的疤痕。
还可将这些组合物用于不希望暴露于UV下的任何皮肤病。
作为实例，可提及痤疮、水痘、带状疱疹、红斑痤疮、一级烧伤、湿疹、色素沉着、光化性皮炎、白癜风、干燥病、卟啉病、妊娠纹、牛皮癣和昆虫叮咬。
本发明还涉及如上定义的组合物在制备旨在保护危险区域、如疤痕的敷料中的用途。
具体实施方式
下述实施例对本发明进行了说明，但并不会限制本发明的保护范围。
实施例1
制备下述组合物。
程序：
用螺旋浆搅拌器以700转/分钟搅拌10分钟，对成分2-6进行混合。然后，在搅拌的同时将硝化纤维素分散于该混合物中，将混合物以1100转/分钟搅拌20分钟，然后以2000转/分钟搅拌30分钟。
滤光能力的测量：
将本发明的组合物以计量的量均匀地铺展在非活性基底上，然后放置干燥，从而使挥发性溶剂蒸发。得到厚度为10μm的膜，并将该膜从基底上分离。
在组合物膜上于体外测量组合物的日光保护因子（SPF），对所述膜加以预先照射从而接近在活体中所遇到的条件。以2-4MED的标准日光剂量预先对膜照射30分钟。所采用的MED值为25mJ/cm2的红斑效力（erythema efficacy），该值相当于在具有4MED/h红斑功效（erythemapower）的最高点处的太阳（标准日光）下暴露15分钟；在290-320nm的UVB光辐射通量为0.365mW/cm2，而在320-400nm的UVA光辐射通量为6.0mW/cm2（UVA/UVB的比为16.5/1）。
用于测量SPF的方法采用了B.L.Diffey和J.Robson在J.S.C.C.，40，127-133，1989年5-6月中所述的原理。
所使用的设备包括：
-配备有UV源和能够传递250-800nm能量通量的双单色仪的“KONTRON 930”分光光度计；
-用于照射的光源：具有标准滤光片和Schott WG 320滤光片的CPS+SUNTEST（ATLAS）。将含有UV滤光片的PMMA片用作参比对照。
由对10μm膜进行3-5次测量得到的SPF平均值为243（±74）。
本发明的膜对于UVA和UVB具有防护性能，并且在UVA和UVB之间具有良好的光谱分布。临界波长为370nm。
实施例2
按照实施例1中的程序制备下列组合物。
根据实施例1中的方法计算SPF平均值。在预照射后，由5次测量得到的SPF平均值为17.10（±0.32）。因此，所述产品确实提供了有效的日光保护。
比较实施例3
制备以下组合物。
程序：
用螺旋浆搅拌器以700转/分钟搅拌10分钟，对成分2-6进行混合。然后，在搅拌的同时将硝化纤维素分散于该混合物中，将混合物以1100转/分钟搅拌20分钟，然后以2000转/分钟搅拌30分钟。
实施例4中的硝化纤维素含量（以干重计的百分比）为20%。实施例4所述的组合物非常粘稠且纤细。因此，无法用刷子铺展实施例4所述的组合物。所得到的膜极不规则且不均匀。
比较实施例4
制备下述组合物。
程序：
用螺旋浆搅拌器以700转/分钟搅拌10分钟，对成分2-6进行混合。然后，在搅拌的同时将硝化纤维素分散于该混合物中，将混合物以1100转/分钟搅拌20分钟，然后以2000转/分钟搅拌30分钟。
实施例5中的硝化纤维素含量（以干重计的百分比）为4.8%。实施例5的组合物非常液态化，并且不能在皮肤上形成足够厚的膜以得到所需的日光保护。所形成的膜极其薄，使得该膜对揉擦和清洗更加敏感。
比较实施例5
制备下述组合物。
程序：
用螺旋浆搅拌器以700转/分钟搅拌10分钟，对成分2-6进行混合。然后，在搅拌的同时将硝化纤维素分散于混合物中，将混合物以1100转/分钟搅拌20分钟，然后以2000转/分钟搅拌30分钟。
过滤能力的测量：
将实施例6的组合物以计量的量均匀地铺展在非活性基底上，然后放置干燥，从而使挥发性溶剂蒸发。得到厚度为10μm的膜，并将该膜从基底上分离。
按照实施例1中的方法测量组合物的日光保护因子（SPF）。
分光光度计显示出
MCX的饱和度高于1.2wt%。此外，示出了
1789的饱和度为1wt%。
Claims (12)
1.一种旨在施用于皮肤上的流体组合物，所述组合物含有聚合物、增塑剂、除水以外的所述聚合物的挥发性溶剂、以及至少一种有机防晒剂，其特征在于，相对于所述组合物的总重量，所述防晒剂的总含量为0.5wt%-2.2wt%，所述挥发性溶剂占所述组合物总重量的60wt%-90wt%，所述聚合物以干重计占所述组合物总重量的5wt%-20wt%。
2.如权利要求1所述的组合物，其特征在于，相对于所述组合物的总重量，所述防晒剂的总含量为1.2wt%-1.8wt%、优选约1.5wt%。
3.如权利要求1或2所述的组合物，其特征在于，所述有机防晒剂为二苯甲酰基甲烷衍生物和吸收UV-B的脂溶性有机防晒剂的混合物。
4.如权利要求3所述的组合物，其特征在于，所述二苯甲酰基甲烷衍生物占所述组合物总重量的0.3wt%-0.7wt%。
5.如权利要求3或4所述的组合物，其特征在于，所述吸收UV-B的脂溶性有机防晒剂占所述组合物总重量的0.8wt%-1.2wt%。
6.如权利要求3-5中任一项所述的组合物，其特征在于，所述有机防晒剂为丁基甲氧基二苯甲酰基甲烷和甲氧基肉桂酸乙基己酯的混合物，所述丁基甲氧基二苯甲酰基甲烷的USAN名称为阿伏苯宗，所述甲氧基肉桂酸乙基己酯的USAN名称为奥西诺酯。
7.如前述权利要求中任一项所述的组合物，其特征在于，相对于所述组合物的总重量，所述组合物包含低于0.5wt%、优选低于0.2wt%的无机防晒剂。
8.如前述权利要求中任一项所述的组合物，其特征在于，所述聚合物为硝化纤维素。
9.如前述权利要求中任一项所述的组合物，其特征在于，所述增塑剂选自蓖麻油、小麦胚芽油、邻苯二甲酸二丁酯、甘油、癸二酸二丁酯、柠檬酸乙酰三丁酯、甘油三乙酸酯及上述物质的混合物。
10.如前述权利要求中任一项所述的组合物，其特征在于，所述聚合物的溶剂选自乙醇、乙酸乙酯及其混合物。
11.如前述权利要求中任一项所述的组合物，其特征在于，所述组合物进一步包含愈合促进剂、抗细菌剂、抗真菌剂、脱色剂、止痛剂、消炎剂、保湿剂、角质层分离剂、维生素或这些化合物的混合物。
12.如前述权利要求中任一项所述的组合物，所述组合物用作保护疤痕的敷料。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1152497 | 2011-03-25 | ||
| FR1152497A FR2972923B1 (fr) | 2011-03-25 | 2011-03-25 | Composition filmogene contenant un filtre solaire, son utilisation pour le traitement des cicatrices |
| PCT/FR2012/050603 WO2012131237A1 (fr) | 2011-03-25 | 2012-03-23 | Composition filmogene contenant un filtre solaire, son utilisation pour le traitement des cicatrices |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103517738A true CN103517738A (zh) | 2014-01-15 |
| CN103517738B CN103517738B (zh) | 2015-09-02 |
Family
ID=46017926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280021506.XA Expired - Fee Related CN103517738B (zh) | 2011-03-25 | 2012-03-23 | 含有防晒剂的流体组合物及其对疤痕进行处理的用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140127148A1 (zh) |
| EP (1) | EP2688650A1 (zh) |
| JP (1) | JP2014508797A (zh) |
| KR (1) | KR20140007922A (zh) |
| CN (1) | CN103517738B (zh) |
| AU (1) | AU2012236013A1 (zh) |
| BR (1) | BR112013024025A8 (zh) |
| CA (1) | CA2830459A1 (zh) |
| FR (1) | FR2972923B1 (zh) |
| MX (1) | MX2013011055A (zh) |
| RU (1) | RU2586293C2 (zh) |
| SG (1) | SG193570A1 (zh) |
| WO (1) | WO2012131237A1 (zh) |
| ZA (1) | ZA201307335B (zh) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104056299A (zh) * | 2014-07-08 | 2014-09-24 | 烟台隽秀生物科技有限公司 | 一种液体护创膜及制备方法 |
| CN104983585A (zh) * | 2015-06-18 | 2015-10-21 | 天津嘉氏堂科技有限公司 | 一种疤痕用防晒硅凝胶及制备方法 |
| CN105249559A (zh) * | 2015-10-27 | 2016-01-20 | 浙江华尔纺织科技有限公司 | 一种美肤护跟套 |
| CN106178094A (zh) * | 2016-07-21 | 2016-12-07 | 贵州金玖生物技术有限公司 | 一种液体创可贴及其制备方法 |
| CN106729963A (zh) * | 2016-12-22 | 2017-05-31 | 苏州迈达医疗器械有限公司 | 一种硅酮凝胶敷料及其生产工艺 |
| CN107041966A (zh) * | 2016-02-05 | 2017-08-15 | 陈明鸿 | 溶剂挥发成形水凝胶基质的组成配方及其制备方法 |
| CN108778234A (zh) * | 2016-03-18 | 2018-11-09 | 小林制药株式会社 | 用于减轻皮肤摩擦的外用制剂 |
| CN112375166A (zh) * | 2020-11-02 | 2021-02-19 | 中国科学技术大学 | 一种具有防晒作用的聚合物、其制备方法及应用 |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0224986D0 (en) | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
| GB0325129D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus in situ |
| US10058642B2 (en) | 2004-04-05 | 2018-08-28 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
| CN101257875A (zh) | 2005-09-06 | 2008-09-03 | 泰科保健集团有限合伙公司 | 具有微型泵的独立伤口敷料 |
| US7779625B2 (en) | 2006-05-11 | 2010-08-24 | Kalypto Medical, Inc. | Device and method for wound therapy |
| HUE049431T2 (hu) | 2007-11-21 | 2020-09-28 | Smith & Nephew | Sebkötözés |
| CA2705896C (en) | 2007-11-21 | 2019-01-08 | Smith & Nephew Plc | Wound dressing |
| GB0722820D0 (en) | 2007-11-21 | 2008-01-02 | Smith & Nephew | Vacuum assisted wound dressing |
| US11253399B2 (en) | 2007-12-06 | 2022-02-22 | Smith & Nephew Plc | Wound filling apparatuses and methods |
| GB0723855D0 (en) | 2007-12-06 | 2008-01-16 | Smith & Nephew | Apparatus and method for wound volume measurement |
| US20130096518A1 (en) | 2007-12-06 | 2013-04-18 | Smith & Nephew Plc | Wound filling apparatuses and methods |
| US8152785B2 (en) | 2008-03-13 | 2012-04-10 | Tyco Healthcare Group Lp | Vacuum port for vacuum wound therapy |
| US9061095B2 (en) | 2010-04-27 | 2015-06-23 | Smith & Nephew Plc | Wound dressing and method of use |
| GB201015656D0 (en) | 2010-09-20 | 2010-10-27 | Smith & Nephew | Pressure control apparatus |
| GB201020005D0 (en) | 2010-11-25 | 2011-01-12 | Smith & Nephew | Composition 1-1 |
| BR112013012785A2 (pt) | 2010-11-25 | 2020-10-20 | Bluestar Silicones France Sas | composição i - ii e produtos e usos das mesmas |
| GB201108229D0 (en) | 2011-05-17 | 2011-06-29 | Smith & Nephew | Tissue healing |
| US9084845B2 (en) | 2011-11-02 | 2015-07-21 | Smith & Nephew Plc | Reduced pressure therapy apparatuses and methods of using same |
| US20150159066A1 (en) | 2011-11-25 | 2015-06-11 | Smith & Nephew Plc | Composition, apparatus, kit and method and uses thereof |
| EP3708196A1 (en) | 2012-03-12 | 2020-09-16 | Smith & Nephew PLC | Reduced pressure apparatus and methods |
| JP6276251B2 (ja) | 2012-03-20 | 2018-02-07 | スミス アンド ネフュー ピーエルシーＳｍｉｔｈ ＆ Ｎｅｐｈｅｗ Ｐｕｂｌｉｃ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ | デューティサイクル閾値の動的決定に基づく減圧療法システムの動作制御 |
| US9427505B2 (en) | 2012-05-15 | 2016-08-30 | Smith & Nephew Plc | Negative pressure wound therapy apparatus |
| HUE047600T2 (hu) | 2012-05-23 | 2020-04-28 | Smith & Nephew | Berendezések negatív nyomású sebgyógyításhoz |
| MX2015001520A (es) | 2012-08-01 | 2015-08-20 | Smith & Nephew | Apósito para heridas. |
| ES2625709T3 (es) | 2012-08-01 | 2017-07-20 | Smith & Nephew Plc. | Apósito de herida |
| GB201317746D0 (en) | 2013-10-08 | 2013-11-20 | Smith & Nephew | PH indicator |
| US10695226B2 (en) | 2013-03-15 | 2020-06-30 | Smith & Nephew Plc | Wound dressing and method of treatment |
| WO2014140606A1 (en) | 2013-03-15 | 2014-09-18 | Smith & Nephew Plc | Wound dressing and method of treatment |
| US20160120706A1 (en) | 2013-03-15 | 2016-05-05 | Smith & Nephew Plc | Wound dressing sealant and use thereof |
| EP3010481B1 (en) * | 2013-06-19 | 2020-04-29 | ELC Management LLC | Methods, compositions, and kit for whitening hyper pigmented spots on skin |
| EP3666237B1 (en) | 2014-06-18 | 2023-11-01 | Smith & Nephew plc | Wound dressing |
| AU2015370583B2 (en) | 2014-12-22 | 2020-08-20 | Smith & Nephew Plc | Negative pressure wound therapy apparatus and methods |
| DK3258942T3 (da) * | 2015-02-16 | 2021-01-25 | Apirx Pharmaceutical Usa Llc | Kosmetiske og topiske sammensætninger omfattende cannabigerol og cannabidiol |
| WO2016164316A1 (en) | 2015-04-06 | 2016-10-13 | 3M Innovative Properties Company | Removable film forming gel compositions and methods for their application |
| CA2982221C (en) * | 2015-04-16 | 2024-01-09 | Siniq Gmbh | Composition for covering and protecting scars |
| US10076594B2 (en) | 2015-05-18 | 2018-09-18 | Smith & Nephew Plc | Fluidic connector for negative pressure wound therapy |
| JP6553961B2 (ja) * | 2015-06-25 | 2019-07-31 | 花王株式会社 | 美白剤 |
| CA3009878A1 (en) | 2015-12-30 | 2017-07-06 | Smith & Nephew Plc | Negative pressure wound therapy apparatus |
| US11090196B2 (en) | 2015-12-30 | 2021-08-17 | Smith & Nephew Plc | Absorbent negative pressure wound therapy dressing |
| JP1586116S (zh) | 2016-02-29 | 2017-09-19 | ||
| USD796735S1 (en) | 2016-02-29 | 2017-09-05 | Smith & Nephew Plc | Mount apparatus for portable negative pressure apparatus |
| US11771820B2 (en) | 2016-03-04 | 2023-10-03 | Smith & Nephew Plc | Negative pressure wound therapy apparatus for post breast surgery wounds |
| BR112018075891B8 (pt) * | 2016-06-16 | 2022-08-09 | Currahee Holding Company Inc | Composição de filtro solar compreendendo uma combinação de um poliéter linear e outros compostos de triagem ultravioleta |
| US11806217B2 (en) | 2016-12-12 | 2023-11-07 | Smith & Nephew Plc | Wound dressing |
| FR3064488B1 (fr) * | 2017-03-31 | 2021-01-01 | Urgo Rech Innovation Et Developpement | Composition contenant un derive de cellulose, un plastifiant, un solvant volatil et un actif, ses utilisations comme pansement |
| FR3064487B1 (fr) * | 2017-03-31 | 2020-10-09 | Urgo Rech Innovation Et Developpement | Composition contenant un derive de cellulose, un plastifiant et un solvant volatil, et ses utilisations comme pansement |
| WO2018229008A1 (en) | 2017-06-14 | 2018-12-20 | Smith & Nephew Plc | Negative pressure wound therapy apparatus |
| WO2021112203A1 (ja) * | 2019-12-06 | 2021-06-10 | 凸版印刷株式会社 | 肌貼付用フィルム、及び、転写シート |
| GB202001212D0 (en) | 2020-01-29 | 2020-03-11 | Smith & Nephew | Systems and methods for measuring and tracking wound volume |
| DE102022207956A1 (de) * | 2022-08-02 | 2024-02-08 | Beiersdorf Aktiengesellschaft | Nachhaltiges hydrophobes Coating für Oberflächen |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB754844A (en) * | 1954-03-03 | 1956-08-15 | Sergius Morgulis | Skin protective composition |
| GB795583A (en) * | 1954-09-14 | 1958-05-28 | Blanche Posnack | Improvements in nitrocellulose-containing liquid cosmetic preparations |
| US3479428A (en) * | 1963-07-12 | 1969-11-18 | Boots Pure Drug Co Ltd | Sunscreen composition and method of using the same |
| US20070048355A1 (en) * | 2005-08-26 | 2007-03-01 | Daniel Perlman | Non-irritating solvent-borne polymeric coatings for application to the skin |
| CN101384239A (zh) * | 2005-12-21 | 2009-03-11 | 先灵-普劳健康护理产品公司 | Uv辐射保护剂组合物 |
| WO2009095808A1 (en) * | 2008-01-30 | 2009-08-06 | L'oreal | A cosmetic composition |
| WO2011008526A2 (en) * | 2009-06-30 | 2011-01-20 | Dow Global Technologies Inc. | Sunscreen-containing dissolvable films |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5601839A (en) * | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
| EE05173B1 (et) * | 2000-05-12 | 2009-06-15 | Krister Olson Bengt | Kombineeritud kompositsioonid k?hre- ja taimeekstraktidest |
| JP2004514728A (ja) * | 2000-12-04 | 2004-05-20 | ロレアル ソシエテ アノニム | 尿素変性チキソトロピー剤を含有するマニキュア液組成物 |
| US7276230B2 (en) * | 2003-12-23 | 2007-10-02 | Avon Products, Inc. | Sunscreen compounds and compositions containing same and methods for use thereof |
| US7378103B2 (en) * | 2004-03-22 | 2008-05-27 | L'oreal | Cosmetic composition comprising a polyglycerolated silicone elastomer |
| JP5074091B2 (ja) * | 2007-05-07 | 2012-11-14 | 有限会社日本健康科学研究センター | 蚊に刺されることを防ぐフィルム忌避製剤 |
| JP2009143830A (ja) * | 2007-12-12 | 2009-07-02 | Nippon Kenko Kagaku Kenkyu Center:Kk | クーリングフィルム製剤 |
| FR2929522B1 (fr) * | 2008-04-04 | 2011-02-11 | Peters Surgical | Composition fluide et transparente pour la formation de pansements pelliculaires protecteurs contre les radiations solaires |
| JP2010126493A (ja) * | 2008-11-28 | 2010-06-10 | Shiseido Co Ltd | 美爪料 |
-
2011
- 2011-03-25 FR FR1152497A patent/FR2972923B1/fr not_active Expired - Fee Related
-
2012
- 2012-03-23 RU RU2013147620/15A patent/RU2586293C2/ru not_active IP Right Cessation
- 2012-03-23 KR KR1020137025087A patent/KR20140007922A/ko not_active Application Discontinuation
- 2012-03-23 EP EP12717361.5A patent/EP2688650A1/fr not_active Withdrawn
- 2012-03-23 AU AU2012236013A patent/AU2012236013A1/en not_active Abandoned
- 2012-03-23 JP JP2014500454A patent/JP2014508797A/ja active Pending
- 2012-03-23 CN CN201280021506.XA patent/CN103517738B/zh not_active Expired - Fee Related
- 2012-03-23 SG SG2013070982A patent/SG193570A1/en unknown
- 2012-03-23 MX MX2013011055A patent/MX2013011055A/es not_active Application Discontinuation
- 2012-03-23 BR BR112013024025A patent/BR112013024025A8/pt not_active Application Discontinuation
- 2012-03-23 CA CA2830459A patent/CA2830459A1/fr not_active Abandoned
- 2012-03-23 WO PCT/FR2012/050603 patent/WO2012131237A1/fr active Application Filing
- 2012-03-23 US US14/007,558 patent/US20140127148A1/en not_active Abandoned
-
2013
- 2013-10-02 ZA ZA2013/07335A patent/ZA201307335B/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB754844A (en) * | 1954-03-03 | 1956-08-15 | Sergius Morgulis | Skin protective composition |
| GB795583A (en) * | 1954-09-14 | 1958-05-28 | Blanche Posnack | Improvements in nitrocellulose-containing liquid cosmetic preparations |
| US3479428A (en) * | 1963-07-12 | 1969-11-18 | Boots Pure Drug Co Ltd | Sunscreen composition and method of using the same |
| US20070048355A1 (en) * | 2005-08-26 | 2007-03-01 | Daniel Perlman | Non-irritating solvent-borne polymeric coatings for application to the skin |
| CN101384239A (zh) * | 2005-12-21 | 2009-03-11 | 先灵-普劳健康护理产品公司 | Uv辐射保护剂组合物 |
| WO2009095808A1 (en) * | 2008-01-30 | 2009-08-06 | L'oreal | A cosmetic composition |
| WO2011008526A2 (en) * | 2009-06-30 | 2011-01-20 | Dow Global Technologies Inc. | Sunscreen-containing dissolvable films |
Non-Patent Citations (1)
| Title |
|---|
| 周洁等: "防晒产品中防晒剂的配比研究和优化方法", 《日用化学工业》, vol. 32, no. 1, 28 February 2002 (2002-02-28), pages 26 - 28 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104056299A (zh) * | 2014-07-08 | 2014-09-24 | 烟台隽秀生物科技有限公司 | 一种液体护创膜及制备方法 |
| CN104983585A (zh) * | 2015-06-18 | 2015-10-21 | 天津嘉氏堂科技有限公司 | 一种疤痕用防晒硅凝胶及制备方法 |
| CN104983585B (zh) * | 2015-06-18 | 2018-09-25 | 天津嘉氏堂科技有限公司 | 一种疤痕用防晒硅凝胶及制备方法 |
| CN105249559A (zh) * | 2015-10-27 | 2016-01-20 | 浙江华尔纺织科技有限公司 | 一种美肤护跟套 |
| CN107041966A (zh) * | 2016-02-05 | 2017-08-15 | 陈明鸿 | 溶剂挥发成形水凝胶基质的组成配方及其制备方法 |
| CN108778234A (zh) * | 2016-03-18 | 2018-11-09 | 小林制药株式会社 | 用于减轻皮肤摩擦的外用制剂 |
| CN106178094A (zh) * | 2016-07-21 | 2016-12-07 | 贵州金玖生物技术有限公司 | 一种液体创可贴及其制备方法 |
| CN106729963A (zh) * | 2016-12-22 | 2017-05-31 | 苏州迈达医疗器械有限公司 | 一种硅酮凝胶敷料及其生产工艺 |
| CN112375166A (zh) * | 2020-11-02 | 2021-02-19 | 中国科学技术大学 | 一种具有防晒作用的聚合物、其制备方法及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013011055A (es) | 2013-11-01 |
| WO2012131237A1 (fr) | 2012-10-04 |
| EP2688650A1 (fr) | 2014-01-29 |
| CA2830459A1 (fr) | 2012-10-04 |
| SG193570A1 (en) | 2013-11-29 |
| FR2972923A1 (fr) | 2012-09-28 |
| AU2012236013A1 (en) | 2013-10-17 |
| US20140127148A1 (en) | 2014-05-08 |
| ZA201307335B (en) | 2015-03-25 |
| BR112013024025A8 (pt) | 2017-10-03 |
| CN103517738B (zh) | 2015-09-02 |
| JP2014508797A (ja) | 2014-04-10 |
| BR112013024025A2 (pt) | 2016-08-23 |
| KR20140007922A (ko) | 2014-01-20 |
| RU2586293C2 (ru) | 2016-06-10 |
| RU2013147620A (ru) | 2015-04-27 |
| FR2972923B1 (fr) | 2013-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103517738B (zh) | 含有防晒剂的流体组合物及其对疤痕进行处理的用途 | |
| CN103458971B (zh) | 含有纤维素、植物油和挥发性溶剂的组合物及其作为敷料的用途 | |
| CN110461299B (zh) | 改善水包油乳液的感官特性的方法 | |
| CN103221025B (zh) | Uv‑过滤剂在制造用来增强白藜芦醇的皮肤渗透性的局部化妆品组合物中的用途 | |
| CN104507469A (zh) | 含有类维生素a的水包油乳液型局部组合物 | |
| AU2014295502A1 (en) | Transparent sunscreen compositions and use thereof | |
| EP3593864A2 (en) | Sunscreen compositions with improved water resistance of uva sunscreen active agents | |
| US9827186B2 (en) | Waxes having oil-in-water self-emulsifying and water gel-forming properties, compositions, uses and methods relating to same | |
| CN104507471A (zh) | 包含溶解的特定类维生素a的呈凝胶形式的局部组合物 | |
| CN105408301A (zh) | 具有更佳紫外防护效用的紫外吸收剂及其组合物 | |
| CN105188853A (zh) | 光防护个人护理组合物 | |
| ES2718848T3 (es) | Composición tópica filmógena y su uso para tratar o prevenir la onicofagia | |
| EP4073170B1 (fr) | Procédé de préparation d'un latex inverse pour composition cosmétique combinant un agent séquestrant particulier et un polyélectrolyte comprenant une fonction acide faible | |
| FR3054791A1 (fr) | Serum cosmetique limpide epaissi et riche en sels, procede pour eclaircir un hydrogel et utilisation en cosmetique | |
| CN105326698A (zh) | 一种含有葡萄柚提取物和迷迭香提取物的防晒乳及其制备方法 | |
| KR101814787B1 (ko) | 스포츠용 물티슈 | |
| EP4027972A1 (fr) | Composition à usage topique anhydre se présentant sous la forme d'une phase dispersée à base d'au moins un diol court dans une phase grasse continue | |
| KR20240127404A (ko) | 수성 에멀젼 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150902 Termination date: 20170323 |